索拉非尼治疗碘难治性分化型甲状腺癌对患者血清Tg、TgAb水平的影响  

Effect of sorafenib on serum Tg and TgAb levels in patients with radioactive iodine-refractory differentiated thyroid carcinoma

作　　者：赵晓琴 罗丽媛 董鹏 ZHAO Xiaoqin;LUO Liyuan;DONG Peng(Department of Respiratory Medicine,Zhangjiakou First Hospital,Hebei,Zhangjiakou 075000,China;不详)

机构地区：[1]河北省张家口市第一医院呼吸科,075000 [2]河北省张家口市第一医院耳鼻咽喉头颈外科,075000

出　　处：《河北医药》2024年第16期2454-2457,2461,共5页Hebei Medical Journal

基　　金：张家口市重点研发计划项目(编号:2121060D)。

摘　　要：目的 分析碘难治性分化型甲状腺癌(Iodine-refractory differentiated thyroid carcinoma, RAIR-DTC)患者使用索拉非尼的效果。方法 选取2020年3月至2022年3月治疗的RAIR-DTC患者30例,按照不同治疗方案分组,A组(13例,常规治疗)和B组(17例,常规治疗+索拉非尼),比较2组治疗1个月、2个月、4个月和6个月效果。结果 治疗1月、2月、4月、6月B组甲状腺球蛋白(Tg)浓度、血管内皮生长因子(VEGF)水平、甲状腺结节(TL)低于A组而甲状腺球蛋白抗体(TgAb)浓度、内皮抑制素(ES)水平高于A组(P<0.05);不同时间点2组不良反应发生率、生存率比较,差异有统计学意义(P>0.05);B组治疗有效率、治疗6月SF-36评分高于A组(P<0.05)。结论 RAIR-DTC患者在治疗中使用索拉非尼,能有效地降低Tg浓度、VEGF水平,提高TgAb浓度、ES水平,且不会进一步增加不良反应风险,安全性和有效性均十分理想,同时能显著提升患者生活质量。Objective To analyze the effects of sorafenib for patients with radioactive iodine-refractory differentiated thyroid cancer(RAIR-DTC).Methods Thirty RAIR-DTC patients treated in our hospital from March 2020 to March 2022 were enrolled,and they were assigned into group A(13 cases,conventional treatment)and group B(17 cases,conventional treatment+sorafenib)according to different treatment regimens.The effects on months 1,2,4,6 of treatment between groups were compared.Results On months 1,2,4,6 of treatment,significantly lower triglyceride(Tg)concentration,vascular endothelial growth factor(VEGF),telomere length(TL),and higher thyroglobulin antibody(TgAb),effect size(ES)were found in group B than those of group A(all P<0.05).The difference was statistically significant in the incidence of adverse reactions,survival rate between groups at different time points(P<0.05).The efficiency and the 36-item Short Form Health Survey(SF-36)score on month 6 of treatment were significantly higher in the group B than in the group A(P<0.05).Conclusion Sorafenib can effectively reduce Tg concentration and VEGF level,increase TgAb concentration and ES level,significantly improve the quality of life in RAIR-DTC patients.It has good safety and effectiveness,and without increasing adverse reactions.

关 键 词：索拉非尼 碘难治性分化型甲状腺癌 血清Tg、TgAb水平 不良反应发生率 

分 类 号：R736.1[医药卫生—肿瘤]